Oncofactory
ERBC is a leading preclinical CRO committed to supporting drug, chemical, and medical device development through a comprehensive suite of scientific services, innovative models, and regulatory expertise. The company emphasizes advancing safety and efficacy, providing trusted GLP and non-GLP services, and fostering innovation in health and safety science. ERBC operates globally with multiple sites, offering services in discovery, toxicology, safety pharmacology, laboratory sciences, NHP supply, and more. It is dedicated to scientific excellence, regulatory compliance, and building long-term partnerships to accelerate the development of safer, smarter health solutions.
Industries
Nr. of Employees
small (1-50)
Oncofactory
Products
Whitepaper: Lead Optimization & Drug-Induced Cardiotoxicity
A joint whitepaper addressing lead optimization strategies, mechanisms of functional cardiotoxicity, regulatory cardiovascular-safety guidelines, and early-detection strategies in preclinical phases.
Whitepaper: Lead Optimization & Drug-Induced Cardiotoxicity
A joint whitepaper addressing lead optimization strategies, mechanisms of functional cardiotoxicity, regulatory cardiovascular-safety guidelines, and early-detection strategies in preclinical phases.
Services
Preclinical efficacy models and translational approaches including PDX models and in vitro/in-silico methods to support lead optimization.
Comprehensive toxicology services across genetic, acute-to-chronic, juvenile, reproductive and developmental endpoints aligned to regulatory requirements.
Safety pharmacology study design and execution to evaluate functional safety risks, including cardiotoxicity assessment strategies.
Bioanalytical services, biomarker assays, immunology testing including flow cytometry, and analytical chemistry to support small molecule and biologic programs.
GCP-compliant clinical bioanalysis and clinical pathology services to produce high-quality clinical trial data.
Breeding, quarantine and supply of non-human primates for translational research and preclinical testing.
Preclinical efficacy models and translational approaches including PDX models and in vitro/in-silico methods to support lead optimization.
Comprehensive toxicology services across genetic, acute-to-chronic, juvenile, reproductive and developmental endpoints aligned to regulatory requirements.
Safety pharmacology study design and execution to evaluate functional safety risks, including cardiotoxicity assessment strategies.
Bioanalytical services, biomarker assays, immunology testing including flow cytometry, and analytical chemistry to support small molecule and biologic programs.
GCP-compliant clinical bioanalysis and clinical pathology services to produce high-quality clinical trial data.
Breeding, quarantine and supply of non-human primates for translational research and preclinical testing.
Expertise Areas
- Preclinical study design and execution (GLP/GCP)
- Non-clinical toxicology and safety pharmacology
- Translational oncology models (PDX)
- In vitro and in-silico New Alternative Methods (NAM)
Key Technologies
- Flow cytometry
- Digital pathology and whole-slide imaging
- In vitro assay development
- In-silico modeling and translational bioinformatics
News & Updates
Participation in NSV 2025 in Montpellier with a scientific poster on antiviral models.
Participation in EUROTOX 2025 congress in Athens with a scientific poster on cytokines.
Participation in Nordic Life Sciences Day 2025 in Gothenburg.
Participation in ACT Annual Meeting 2025 in Phoenix with experts discussing toxicology.
Participation in Tumor Model Summit 2025 in London with in vivo and in vitro tumor modeling.
Participation in BIO Korea 2025 in Seoul, South Korea.
Participation in NSV 2025 in Montpellier with a scientific poster on antiviral models.
Participation in EUROTOX 2025 congress in Athens with a scientific poster on cytokines.
Participation in Nordic Life Sciences Day 2025 in Gothenburg.
Participation in ACT Annual Meeting 2025 in Phoenix with experts discussing toxicology.
Participation in Tumor Model Summit 2025 in London with in vivo and in vitro tumor modeling.
Participation in BIO Korea 2025 in Seoul, South Korea.